Latest news with #PD
Business Wire
3 hours ago
- Business
- Business Wire
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
SAN DIEGO--(BUSINESS WIRE)-- Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. 'As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need,' said Dr. Russ Lebovitz, CEO and co-founder of Amprion. 'Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC.' Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn.
Toronto Star
a day ago
- Business
- Toronto Star
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor. The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the 'Pre-Funded Warrants') to purchase 984,736 common shares, no par value (the 'Common Shares'). The Pre-Funded Warrants were sold at a price of $0.8124 per share, which represents the per share offering price for the Common Shares less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The Pre-Funded Warrants will be immediately excercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The closing of the offering is expected to occur on or about July 24, 2025, subject to the satisfaction of customary closing conditions.
Hamilton Spectator
a day ago
- Business
- Hamilton Spectator
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor. The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the 'Pre-Funded Warrants') to purchase 984,736 common shares, no par value (the 'Common Shares'). The Pre-Funded Warrants were sold at a price of $0.8124 per share, which represents the per share offering price for the Common Shares less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The Pre-Funded Warrants will be immediately excercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The closing of the offering is expected to occur on or about July 24, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to ProMIS are expected to be approximately $0.8 million, before deducting certain offering expenses. ProMIS intends to use the net proceeds from the offering towards its further advancement of the clinical development of PMN310, its lead therapeutic candidate, as well as for working capital and other general corporate expenses. The securities above are being offering pursuant to a shelf registration statement on Form S-3 (333-274658) that was filed with the Securities and Exchange Commission (the 'SEC') on September 22, 2023, amended on September 27, 2023 and declared effective by the SEC on September 29, 2023. The offering is being made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at . This press release does not constitute an offer to sell or the solicitation of offers to buy any of the securities being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About ProMIS Neurosciences Inc. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN). Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'pleased to', 'look forward to', 'potential to', 'targets', 'expects' or 'does not expect', 'is expected', 'excited about', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the the expected timing for the closing of the offering and the anticipated use of proceeds from the offering. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical results or early results may not be indicative of future results, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information: Visit us at Please submit media inquiries to info@ For Investor Relations, please contact: Kaytee Bock Zafereo
Time of India
4 days ago
- Health
- Time of India
Having cereal for breakfast? It could increase the risk of Parkinson's disease
A recent study reveals a potential link between high consumption of ultra-processed foods and early signs of Parkinson's disease. Researchers found that individuals consuming 11 or more servings of such foods daily faced a significantly higher risk of developing early indicators of the condition. Breakfast is considered the most important meal of the day. From fueling the body with energy to jumpstarting metabolism, breakfast plays a crucial role in maintaining overall health. But what do you have for breakfast? Cereals, bacon, sausage? Well, then it's time to rethink your breakfast options. A recent study has found that people who eat foods like cold breakfast cereal, cookies, and hot dogs are more likely to have early signs of Parkinson's disease. The study found that people who consumed more ultra-processed foods were more at risk of Parkinson's disease when compared to those who ate very few ultra-processed foods. The findings of the study are published in Neurology . What is Parkinson's disease Parkinson's disease is a progressive, degenerative brain condition that affects the nervous system. It causes nerve cells (neurons) in parts of the brain to weaken, become damaged, and die, leading to symptoms that include problems with movement, tremor, stiffness, and impaired balance. As symptoms progress, people with Parkinson's disease (PD) may have difficulty walking, talking, or completing other simple tasks. Diet and Parkinson's disease To understand the link between diet and Parkinson's disease, the researchers looked for signs of prodromal Parkinson's disease, which is the earliest stage, when neurodegeneration begins, but more characteristic symptoms of Parkinson's disease, like tremors, balance problems, and slow movement, have not yet begun. Such early symptoms show up years or even decades before the typical symptoms start. 'Eating a healthy diet is crucial as it has been associated with a lower risk of neurodegenerative diseases, and the dietary choices we make today can significantly influence our brain health in the future. There's growing evidence that diet might influence the development of Parkinson's disease. Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease,' study author Xiang Gao, MD, PhD, of the Institute of Nutrition, Fudan University in Shanghai, China, said in a statement. The study Source: Wikipedia The researchers looked at 42,853 people with an average age of 48 who did not have Parkinson's disease at the start of the study. These participants were followed up for 26 years. To keep a check on their health, they were asked to take regular medical exams and complete health questionnaires. The results were reviewed to see if they had early signs of Parkinson's disease. The signs include rapid eye movement sleep behavior disorder, constipation, depressive symptoms, body pain, impaired color vision, excessive daytime sleepiness, and reduced ability to smell. The participants also completed a food diary every two to four years, listing what they ate and how often. The findings (Pic courtesy: iStock) The researchers observed if the participants consumed ultra-processed foods including sauces, spreads, or condiments; packaged sweets; snacks or desserts; artificially or sugar-sweetened beverages; animal-based products; yogurt or dairy-based desserts; and packaged savory snacks. One serving was equivalent to a single can of soda, one ounce of potato chips, one slice of packaged cake, a single hot dog or one tablespoon of ketchup. They also calculated how many ultra-processed foods participants ate on average per day. Based on this, they were categorized into five groups. The highest group ate 11 or more servings of ultra-processed food per day on average. The lowest group ate an average of fewer than three servings per day. Kelly Osbourne Erupts Over Viral 'Ozzy Is Dying' Rumours They found that participants who ate 11 or more servings of ultra-processed foods per day had a 2.5-fold higher likelihood of having three or more early signs of Parkinson's disease compared to those consuming fewer than three servings per day. They also found that eating more ultra-processed foods was tied to an increased risk for nearly all symptoms except constipation. 'Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health. More studies are needed to confirm our finding that eating less processed food may slow down the earliest signs of Parkinson's disease,' Gao said. It is also important to understand that this study does not prove that eating more ultra-processed foods causes early signs of Parkinson's disease; it only shows an association.
Local Italy
6 days ago
- Politics
- Local Italy
Why are Italy's left-wing parties struggling to win support?
Almost three years after its historic election victory, Meloni's far-right Brothers of Italy party remains the most popular, polling at 29 percent – above the 26 percent it secured in the September 2022 vote, according to the latest YouTrend survey. The prime minister herself tops polls of party leaders with an approval rating of 45 percent, according to Ipsos. The traditional left is struggling across Europe, where populist parties – particularly the far right – have gained ground in recent years. And in Italy, which once had Western Europe's largest Communist Party, "there is a crisis in the left", commented Paolo Borioni, professor of political science at Rome's Sapienza University. He said left-wing parties had "severed their historical class ties", notably with those on lower incomes. The opposition is dominated by the centre-left Democratic Party (PD), currently polling at around 22 percent, and the Five Star Movement, with around 13 percent. Marc Lazar, a professor at Sciences Po Paris and Luiss University in Rome, said both are paying the price for their record in government, where they "disappointed" as they "did not address social issues." The PD adopted several measures that liberalised the labour market and cut public spending while in power after the 2013 election. Since then, they have lost over three million votes. For its part, the Five Star triumphed in 2018 elections on an anti-establishment message, only to ally with its declared enemies while in government. Gaza, Ukraine The PD chose a new leader after the 2022 elections, Elly Schlein, who has tacked further left, championing a national minimum wage and increased spending on education and healthcare. The Five Star under former premier Giuseppe Conte is also pushing for a minimum wage and a basic income for the most vulnerable. "Meloni, like all the right, claims to defend the people but only defends the big hedge funds, the big banks," Riccardo Ricciardi, president of the Five Star parliamentary group in the Chamber of Deputies, told AFP. Both parties have also sought to mobilise public concern about rising defence budgets and Israel's offensive in Gaza. Five Star threw its weight behind a large protest in Rome last month against rearmament, an issue that Lazar noted "poses a challenge to Giorgia Meloni" in a country with a long tradition of peace movements. But divisions on the issue within the PD have undermined the opposition's ability to attack the government. Both the PD and Five Star also backed a huge protest on Gaza, but some PD supporters accused Schlein of being slow to take up the issue. "They lack courage," lamented Arianna D'Archivio, a 23-year-old student organiser at the rearmament protest. A third large demonstration took place for Pride, an explicit challenge to Meloni's socially conservative agenda. Vote alliances Meloni shares government with the smaller far-right League party and the centre-right Forza Italia, which gives her a majority in parliament. Despite their differences, PD and Five Star have tried teaming up at the ballot box, with joint candidates winning regional elections in Emilia-Romagna and Umbria in 2024, as well as the northern city of Genoa in May. They also both supported a recent referendum on labour market reform, although it failed due to low turnout. Schlein insisted the PD was making progress. "We will happily leave the polls to Meloni's right, but we are winning elections," she told AFP at a recent event. The PD performed better than expected in last year's European Parliament elections, winning 24 percent of the vote, compared to 29 percent for Meloni's party – but with a historically low turnout. Disconnected For Dario Salvetti, an auto industry worker from Florence, the left is "broken" and "disconnected from the masses" in a country where salaries have been stalled for decades and one in ten Italians is classified as living in poverty. For analyst Borioni, there is "no rightward shift in the population in Italy," just more people are abandoning the left. Activists meanwhile see the problem as politics, not the left itself. Francesca Ciuffi, a 27-year-old trade unionist in the textile hub of Prato, noted their recent successes in improving conditions for workers following strikes. "The big unions and left-wing parties have abandoned their role," she said. By AFP's Piera ROCCO DI TORREPADULA
